Primary Pleural Melanoma: A Case Report and Literature Review

Kojin Murakami¹, Kazunori Tobino¹ ², Yoshikazu Yamaji¹, Ryunosuke Ooi¹, Miyuki Munechika¹, Yuki Enzan¹, Yuki Yoshimatsu¹, Kosuke Tsuruno¹, Hiromi Ide¹ and Noriyuki Ebi¹

Abstract:
Primary pleural melanoma is an extremely rare neoplasm, and to the best of our knowledge, there have been only 8 case reports of this condition in the English literature. We herein report a rare case in which the cytological and immunocytochemical analyses of pleural fluid and ultrasonography (US)-guided biopsy of a pleural lesion were useful for the diagnosis primary pleural melanoma. This case highlights the importance of careful physical examinations, cytomorphologic and immunocytochemical analyses of pleural fluid, as well as the utility of US-guided biopsy of the pleural lesions in the diagnosis of primary pleural melanoma.

Key words: pleura, melanoma, ultrasonography-guided biopsy

Introduction
Primary pleural melanoma is an extremely rare neoplasm. To the best of our knowledge, there have been only 8 case reports on this condition in the English literature (1-10). It is difficult to distinguish whether a pleural melanoma is primary or metastatic. Wilson proposed clinical criteria for the diagnosis of primary pulmonary melanoma (9), and it is thought to be relevant for the diagnosis of primary pleural melanoma.

We herein report a rare case in which the cytological and immunocytochemical analyses of pleural fluid and ultrasonography-guided biopsy of pleural lesions were useful for the diagnosis of primary pleural melanoma. We also present a literature review of reported cases of primary pleural melanoma.

Case Report
An 83-year-old Japanese man presented with left-sided chest pain and dyspnea, which had lasted for a few hours. He had a history of old myocardial infarction, paroxysmal atrial fibrillation, hyperlipidemia, hearing loss, and corneal transplantation in both eyes for corneal leukoma. He drank alcoholic beverages occasionally and was a non-smoker. His initial vital signs were unremarkable. There was no lymphadenopathy, hepatosplenomegaly, or edema. Decreased breath sounds and dullness were present at the base of the left lung. A cardiovascular examination was normal. Laboratory test values, including values reflecting the liver, renal, and thyroid function, were unremarkable. The patient’s serum albumin and brain natriuretic peptide levels were within the normal limits. Chest radiography showed a large amount of pleural effusion in the left hemithorax, and chest computed tomography (CT) showed multiple nodular pleural thickening with pleural effusion in the left hemithorax (Fig. 1). Thoracentesis revealed bloody pleural effusion. Cytology of the pleural fluid revealed loosely aggregated large malignant cells, which had large eccentric nuclei and granular cytoplasmic melanin pigment. Immunocytochemistry revealed that the malignant cells were positive for S-100 and human melanoma black-45 (HMB-45), and negative for calretinin, D2-40, desmin, epithelial membrane antigen (EMA), thyroid...
transcription factor 1 (TTF-1), and Napsin A, which further supported the diagnosis of melanoma (Fig. 2). Ultrasonography (US)-guided transthoracic biopsy of the pleural lesion was performed, and both histological and immunohistochemical examinations confirmed the diagnosis (Fig. 2). Detailed physical examinations of the patient failed to reveal any site of primary melanoma in the skin, eyes, oral cavity, genital or anal regions.

The patient received chemical pleurodesis using OK-432 for the relief of dyspnea due to massive plural effusion. Thereafter, he declined any further treatment, and died of respiratory failure at 1 month after the diagnosis. The autopsy revealed a muddy black-colored tumor that had widely disseminated in the left thoracic cavity (Fig. 3). The tumor was mainly located in the left visceral pleura and invaded the left lung tissue. Moreover, the tumor also disseminated to the left parietal pleura, diaphragm, peritoneum and mesenterium. No primary site was found at any location, including the skin and other mucous membranes. Based on these findings, the patient was diagnosed with primary pleural melanoma. Unfortunately, at the time of the diagnosis of this patient, there were no commercially available tests for the assessment of the BRAF mutation and programmed death-ligand (PD-L1) expression status; thus, we could not
obtain these results.

**Discussion**

Melanoma develops by malignant transformation of melanocytes and commonly originates from the skin. It also less commonly originates from the retina, digestive tract, liver, upper respiratory tract, lung, urethra and prostate (10-15). Although pleural metastasis from cutaneous melanoma is relatively common, primary pleural melanoma is extremely rare. To the best of our knowledge, there have only been 8 case reports of this condition (Table) (1-8).

Chronic stress, such as ultraviolet ray and white race are known risk factors for melanoma. Jeremy and Earle observed a 5% increase in the risk of developing melanoma in patients with sizable congenital nevi (16). Olsen et al. reported that individuals exhibiting 25 or more of typical congenital nevi or 1 or more atypical skin nevi may be at high risk of melanoma (17). Our patient did not have multiple or atypical nevi. In spite of the unclear pathogenesis of primary pleural melanoma, several hypotheses have been proposed (16, 17): (1) growth from pigment blast cells, (2) growth from multipotent stem cells, (3) squamous metaplasia, (4) growth from aberrant skin nevus cells in the pleura which transfer along the lymphogenous pathway, and (5) disappearance of the primary tumor after metastasis in the pleura.

Among the 9 reported cases of primary pleural melanoma, including our case, the main symptoms were dyspnea (n=8), chest pain (n=4), and cough (n=3). All cases showed moderate to a massive pleural effusion, the gross appearance of which was hemorrhagic or black. On the other hand, Chen et al. reported that pleural effusion was not common in patients with metastatic pleural melanoma (18, 19). This difference between primary and metastatic pleural melanoma may be useful for differentiation. The color of the pleural fluid is an essential clue to diagnosing this condition. Other reported causes of black pleural effusion include *Aspergillus niger* pleuritis, *Rhizopus oryzae* pleuritis, pancreatic pleural effusion, and hemothorax (20). In our patient, cytological and immunohistochemical examinations of the plural fluid triggered the suspicion of melanoma, and a definitive diagnosis was made based on the US-guided biopsy findings. To the best of our knowledge, this is the first case of primary pleural melanoma diagnosed by US-guided biopsy. The following methods are used to obtain biopsy specimens of pleural lesions: percutaneous pleural biopsy with Cope and Abrams needles, CT-guided biopsy, thoracoscopic biopsy, and thoracotomy. There have been no studies about the diagnostic accuracy of these methods for primary pleural melanoma because of its rarity. In malignant mesothelioma, which is the most frequent primary pleural malignancy, thoracoscopic biopsy has been reported as the standard method for obtaining specimens for a histological diagnosis, the accuracy of which is >95% (21, 22). In patients with a poor performance status or relatively large lesions, CT-guided biopsy is suggested because of its lower complication rate and favorable diagnostic accuracy (23). In comparison to CT-guided biopsy, US-guided biopsy has been reported to have the following advantages: a lower complication rate, lower cost, shorter procedure time, and lower radiation exposure (24, 25). Our patient was elderly with a poor PS and

**Figure 3. Autopsy revealed a muddy black-colored tumor widely disseminated in the left thoracic cavity.**

**Table. Treatment and Prognosis of the Previously Reported Case Reports and Our Patient.**

| Reference | Age | Sex | Treatment                                         | Prognosis          |
|-----------|-----|-----|--------------------------------------------------|--------------------|
| [1]       | 49  | M   | Adriamycin                                       | 10 months          |
| [2]       | 61  | M   | The patient refused treatment.                   | Not available      |
| [3]       | 50  | M   | Chemical pleurodesis                             | Not available      |
|           |     |     | Dacarbazine + Cisplatin + Vincristine            | (at least 7 months)|
| [4]       | 49  | M   | None                                             | 2.5 months         |
| [5]       | 46  | M   | Chemical pleurodesis                             | Not available      |
|           |     |     | Dacarbazine + Cisplatin + Vincristine            | (at least 7 months)|
| [6]       | 36  | F   | The patient refused treatment.                   | 1 month            |
| [7]       | 61  | M   | Dacarbazine + Cisplatin + Interferon-α2b        | 2 months           |
| [8]       | 40  | M   | The patient refused treatment.                   | 1 month            |
| Present Case | 83  | M   | Chemical pleurodesis                             | 1 month            |
|           |     |     | The patient refused treatment.                   |                    |

3275
had large lesions. Thus, we chose to perform US-guided biopsy and were able to obtain a diagnosis without complications.

There are no established diagnostic criteria for primary pleural melanoma. Jensen and Egedorf proposed the following six clinical diagnostic criteria for primary pulmonary melanoma (not primary pleural melanoma): (1) no previously removed pigmented skin tumors, (2) no removed ocular tumors, (3) a solitary tumor in the surgical specimen, (4) tumor morphology compatible with a primary tumor, (5) no demonstrable melanoma in other organs at the time of operation, and (6) autopsy without primary melanomas being demonstrated elsewhere (20). These criteria are considered appropriate for the diagnosis of primary pleural melanoma.

In our patient, the autopsy revealed no primary site other than the left pleural cavity, where the disease extent was most severe. We thought that he met 5 of the 6 items of the diagnostic criteria, with the exception being “(3) a solitary tumor in the surgical specimen”. Since it was impossible to meet the sixth criterion before death (“autopsy without primary melanomas being demonstrated elsewhere”), we believe our patient was definitively diagnosed while he was alive.

The treatment options for primary pleural melanoma include surgery, radiotherapy, and chemotherapy (e.g., adriamycin, and cisplatin plus dacarbazine). However, despite these various treatment options, the prognosis is poor. In fact, 5 of the 8 reported cases of primary pleural melanoma died within 1 year of the diagnosis (1-8) (Table). In recent years, molecularly targeted drugs and immune checkpoint inhibitors have been introduced in chemotherapy for malignant melanoma and are associated with better treatment outcomes. Thus, the benefit of these new drugs may be produced in primary pleural melanoma in the future.

**Conclusion**

We experienced a rare case of primary pleural melanoma. This case highlights the importance of careful physical examinations, and cytomorphic and immunocytochemical analyses of pleural fluid, as well as the utility of US-guided biopsy of the pleural lesions in the diagnosis of primary pleural melanoma.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Smith S, Opipari MI. Primary pleural melanoma. A first reported case and literature review. J Thorac Cardiovasc Surg 75: 827-831, 1978.
2. Um SW, Yoo CG, Lee CT, Han SK. Shim YS, Kim YW. Apparent primary pleural melanoma: case report and literature review. Respir Med 97: 586-587, 2003.
3. Mohanty PP, Pasricha R, Gupta A, Jain M, Datta NR. Malignant melanoma of pleura in a patient with giant congenital "bathing suit" hairy nevus. Int J Clin Oncol 9: 410-412, 2004.
4. Ohata Y, Haga T, Ogata S, Nakanishi K, Kawai T. Malignant amelanotic melanoma of the pleura without primary skin lesion: an autopsy case report. Acta Med Okayama 63: 379-384, 2009.
5. Shameem M, Ahktar J, Baneen U, et al. Malignant melanoma presenting as an isolated pleural effusion. Monaldi Arch Chest Dis 75: 138-140, 2011.
6. Cheng L, Nie J, Li J, Wang J, Jiang K. Primary pleural malignant melanoma with rapid progression. Ann Thorac Surg 98: 334-336, 2014.
7. Wang Q, Chen J, Dassarath M, et al. Primary malignant melanoma of the pleura with rapid progression: a case report and literature review. Onkol Lett 9: 2713-2715, 2015.
8. Agarwal P, Nambiyar K, Manju Kaushal, Bhardwaj M. Primary malignant melanoma of pleura. A case report and literature review. Diagn Cytopathol 44: 648-652, 2016.
9. Wilson RW, Moran CA. Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol 21: 1196-1202, 1997.
10. DasGupta TK, Brasfield RD, Paglai MA. Primary melanomas in unusual sites. Surg Gynecol Obstet 128: 841-848, 1969.
11. Khalid U, Saleem T, Imam AM, Khan MR. Pathogenesis, diagnosis and management of primary melanoma of the colon. World J Surg Oncol 9: 14, 2011.
12. Gong L, Li YH, Zhao JY, Wang XW, Zhu SJ, Zhang W. Primary malignant melanoma of the liver: a case report. World J Gastroenterol 14: 4968-4971, 2008.
13. Doubali M, Chouaib A, Khallouk A, et al. Primary malignant melanoma of prostate. Urol Ann 2: 76-77, 2010.
14. Cho ST, Song HC, Cho B, et al. Primary malignant melanoma of the female urethra. Korean J Urol 53: 206-208, 2012.
15. Wilson RW, Moran CA. Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol 21: 1196-1202, 1997.
16. Jeremy N, Earle C. Congenital melanocytic nevi and the risk of malignant melanoma: establishing a guideline for primary-care physicians. Einstein J Biol Med 27: 59-66, 2011.
17. Olsen CM, Carroll HJ, Whitman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 3: 233-245, 2010.
18. Chen JT, Dahmash NS, Ravin CE, et al. Metastatic melanoma in the thorax: report of 130 patients. AJR Am J Roentgenol 137: 293-298, 1981.
19. Webb WR, Gansu G. Thoracic metastases in malignant melanoma: a radiographic survey of 65 patients. Chest 71: 176-181, 1977.
20. Jensen OA, Egedorf J. Primary malignant melanoma of the lung. Scand J Respir Dis 48: 127-135, 1967.
21. Grossebner MW, Arifi AA, Goddard M, et al. Mesothehioma-VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 16: 619-623, 1999.
22. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72: 389-393, 1993.
23. van Gelder T, Hoogsteden HC, Vandenbroucke JP, et al. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. Virchows Arch A Pathol Anat Pathol 418: 315-317, 1991.
24. Sheith S, Harmer UM, Stanley DB, Wheeler JH, Smith PA. US guidance for thoracic biopsy: a valuable alternative to CT. Radiology 210: 721-726, 1999.
25. Yamamoto N, Watanebe T, Yamada K, et al. Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy. J Thorac Dis 11: 936-943, 2019.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).